Literature DB >> 16616566

Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide.

Tatsuo Nishioka1, Shunji Tomatsu, Monica A Gutierrez, Ken-ichi Miyamoto, Georgeta G Trandafirescu, Patricia L C Lopez, Jeffrey H Grubb, Rie Kanai, Hironori Kobayashi, Seiji Yamaguchi, Gary S Gottesman, Richard Cahill, Akihiko Noguchi, William S Sly.   

Abstract

Hypophosphatasia is caused by deficiency of activity of the tissue-nonspecific alkaline phosphatase (TNSALP), resulting in a defect of bone mineralization. Enzyme replacement therapy (ERT) with partially purified plasma enzyme was attempted but with little clinical improvement. Attaining clinical effectiveness with ERT for hypophosphatasia may require delivering functional TNSALP enzyme to bone. We tagged the C-terminal-anchorless TNSALP enzyme with an acidic oligopeptide (a six or eight residue stretch of L-Asp), and compared the biochemical properties of the purified tagged and untagged enzymes derived from Chinese hamster ovary cell lines. The specific activities of the purified enzymes tagged with the acidic oligopeptide were the same as the untagged enzyme. In vitro affinity experiments showed the tagged enzymes had 30-fold higher affinity for hydroxyapatite than the untagged enzyme. Lectin affinity chromatography for carbohydrate structure showed little difference among the three enzymes. Biodistribution pattern from single infusion of the fluorescence-labeled enzymes into mice showed delayed clearance from the plasma up to 18 h post infusion and the amount of tagged enzyme retained in bone was 4-fold greater than that of the untagged enzyme. In vitro mineralization assays with the bone marrow from a hypophosphatasia patient using each of the three enzymes in the presence of high concentrations of pyrophosphate provided evidence of bone mineralization. These results show the anchorless enzymes tagged with an acidic oligopeptide are delivered efficiently to bone and function bioactively in bone mineralization, at least in vitro. They suggest potential advantages for use of these tagged enzymes in ERT for hypophosphatasia, which should be explored.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616566      PMCID: PMC2587042          DOI: 10.1016/j.ymgme.2006.02.012

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  61 in total

1.  The interaction of wheat germ agglutinin with sialoglycoproteins. The role of sialic acid.

Authors:  V P Bhavanandan; A W Katlic
Journal:  J Biol Chem       Date:  1979-05-25       Impact factor: 5.157

2.  Serum alkaline phosphatase, serum pyrophosphatase, phosphorylethanolamine and inorganic pyrophosphate in plasma and urine. A genetic and clinical study of hypophosphatasia.

Authors:  S A Sørensen; H Flodgaard; E Sørensen
Journal:  Monogr Hum Genet       Date:  1978

3.  Different lectin affinities in rat alkaline phosphatase isozymes: multiple forms of the isozyme isolated by heterogeneities of sugar moieties.

Authors:  I Koyama; Y Sakagishi; T Komoda
Journal:  J Chromatogr       Date:  1986-01-10

4.  Silver staining methods for polyacrylamide gel electrophoresis.

Authors:  C R Merril; D Goldman; M L Van Keuren
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Can biological calcification occur in the presence of pyrophosphate?

Authors:  J L Meyer
Journal:  Arch Biochem Biophys       Date:  1984-05-15       Impact factor: 4.013

6.  Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation.

Authors:  F S Furbish; C J Steer; N L Krett; J A Barranger
Journal:  Biochim Biophys Acta       Date:  1981-04-03

7.  Infantile hypophosphatasia: normalization of circulating bone alkaline phosphatase activity followed by skeletal remineralization. Evidence for an intact structural gene for tissue nonspecific alkaline phosphatase.

Authors:  M P Whyte; H L Magill; M D Fallon; H G Herrod
Journal:  J Pediatr       Date:  1986-01       Impact factor: 4.406

8.  Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: results in three additional patients.

Authors:  M P Whyte; W H McAlister; L S Patton; H L Magill; M D Fallon; W B Lorentz; H G Herrod
Journal:  J Pediatr       Date:  1984-12       Impact factor: 4.406

9.  Identification of two binding sites for wheat-germ agglutinin on polylactosamine-type oligosaccharides.

Authors:  J T Gallagher; A Morris; T M Dexter
Journal:  Biochem J       Date:  1985-10-01       Impact factor: 3.857

10.  Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease.

Authors:  M P Whyte; R Valdes; L M Ryan; W H McAlister
Journal:  J Pediatr       Date:  1982-09       Impact factor: 4.406

View more
  37 in total

1.  Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome.

Authors:  Shunji Tomatsu; Adriana M Montaño; Vu Chi Dung; Amiko Ohashi; Hirotaka Oikawa; Toshihiro Oguma; Tadao Orii; Luis Barrera; William S Sly
Journal:  Mol Ther       Date:  2010-03-23       Impact factor: 11.454

Review 2.  Selective drug delivery to bone using acidic oligopeptides.

Authors:  Junko Ishizaki; Yoshihiro Waki; Tatsuo Takahashi-Nishioka; Koichi Yokogawa; Ken-Ichi Miyamoto
Journal:  J Bone Miner Metab       Date:  2008-11-19       Impact factor: 2.626

3.  Hypophosphatasia - pathophysiology and treatment.

Authors:  José Luis Millán; Horacio Plotkin
Journal:  Actual osteol       Date:  2012-09-01

Review 4.  Morquio A syndrome: diagnosis and current and future therapies.

Authors:  Shunji Tomatsu; Eriko Yasuda; Pravin Patel; Kristen Ruhnke; Tsutomu Shimada; William G Mackenzie; Robert Mason; Mihir M Thacker; Mary Theroux; Adriana M Montaño; Carlos J Alméciga-Díaz; Luis A Barrera; Yasutsugu Chinen; William S Sly; Daniel Rowan; Yasuyuki Suzuki; Tado Orii
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

Review 5.  Gene therapy for Mucopolysaccharidoses.

Authors:  Kazuki Sawamoto; Hui-Hsuan Chen; Carlos J Alméciga-Díaz; Robert W Mason; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-12-26       Impact factor: 4.797

6.  Bone-targeting endogenous secretory receptor for advanced glycation end products rescues rheumatoid arthritis.

Authors:  Tatsuo Takahashi; Sayaka Katsuta; Yusuke Tamura; Nozomi Nagase; Keita Suzuki; Masaaki Nomura; Shunji Tomatsu; Ken-Ichi Miyamoto; Shinjiro Kobayashi
Journal:  Mol Med       Date:  2013-07-24       Impact factor: 6.354

7.  Bone-targeting of quinolones conjugated with an acidic oligopeptide.

Authors:  Tatsuo Takahashi; Koichi Yokogawa; Naoki Sakura; Masaaki Nomura; Shinjiro Kobayashi; Ken-ichi Miyamoto
Journal:  Pharm Res       Date:  2008-07-29       Impact factor: 4.200

8.  Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model.

Authors:  Daniel J Rowan; Shunji Tomatsu; Jeffrey H Grubb; Bisong Haupt; Adriana M Montaño; Hirotaka Oikawa; Angela C Sosa; Anping Chen; William S Sly
Journal:  Mol Genet Metab       Date:  2012-07-14       Impact factor: 4.797

Review 9.  Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546

10.  A review of treatment of Pompe disease in infants.

Authors:  Yin-Hsiu Chien; Wuh-Liang Hwu
Journal:  Biologics       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.